Abstract
Background
Current knowledge in long-term results of tricuspid valve replacement is limited. Present study reviews our experience from a consecutive series.
Methods
We retrospectively studied the early and late results of 32 consecutive patients (7 male and 25 female; mean age 60.2 ± 18.1 years) undergoing bioprosthetic tricuspid valve replacement between 1985 and 2010. The etiology is rheumatic in 38 %, congenital in 3 %, endocarditis in 9 %, and functional in 50 %. Patients underwent isolated valve replacement. The remaining underwent combined aortic and tricuspid (n = 5, 16 %), mitral tricuspid (n = 15, 47 %), and aortic, mitral, and tricuspid (n = 1, 3 %) valve replacement. Preoperative liver dysfunction was evaluated using Model for End-stage Liver Disease (MELD) score. Mean follow-up was 5.6 ± 6.8 years (ranging from 0 to 25.0 years).
Results
Hospital mortality was 19 %. On univariate logistic regression analysis, NYHA class IV (p = 0.039, odds ratio 11.3, 95 % confidence interval 1.2–112.5), MELD score (>10) (p = 0.011, odds ratio 21.0, 95 % confidence interval 12.0–222.0) and congestive liver (p = 0.05, odds ratio 9.4, 95 % confidence interval 1.0–93.5) were incremental risk factors for hospital death. The 15- and 25-year actuarial survival were 56.5 ± 10.3 % and 45 ± 13.0 %, respectively. Multivariate analysis using Cox proportional hazard model showed MELD score (p = 0.024, hazard ratio 7.0, 95 % confidence interval 2.1–23.9) and postoperative pulmonary hypertension (p = 0.012, hazard ratio 4.4, 95 % confidence interval 1.4–14.1) were significantly associated with decreased survival. At 15 years, freedom rates from tricuspid valve reoperation, anticoagulation-related bleeding, and valve related events were 85.7 ± 13.2 %,95.7 ± 4.3 % and 81.8 ± 13.2 %, respectively. The linearized incidence of structural valve deterioration was 0.50 %/patient-year, anticoagulation-related bleeding was 0.94 %/patient-year, and valve-related events were 1.52 %/patient-year.
Conclusion
Preoperative hepatic congestion and liver dysfunction which were indicated by the MELD score >10 were associated with poor outcome for patients undergoing tricuspid valve replacement. The MELD score is useful to predict the morality among these patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dalrymple-Hay MJR, Leung Y, Ohri SK, Ross HJK, Liversey SA, Monro JL, et al. Tricuspid valve replacement: bioprosthesis are preferable. J Heart Valve Dis. 1999;8:644–8.
Tokunaga S, Masuda M, Shiose A, Tomita Y, Morita S, Tominaga R. Long-term results of isolated tricuspid valve replacement. Asian Cardiovasc Thorac Ann. 2008;16:25–8.
Civelek A, Ak K, Akgun S, et al. Tricuspid valve replacement: an analysis of risk factors and outcomes. Thorac Cardiovasc Surg. 2008;56:456–60.
Mangoni AA, DiSalvo TG, Vlahakes GJ, Polanczyk CA, Fifer MA. Outcome following isolated tricuspid valve replacement. Eur J Cardiothorac Surg. 2001;19:68–73.
Glowers DD, White WD, Smith LR, et al. In-hospital and long-term outcome after porcine tricuspid valve replacement. J Thorac Cardiovasc Surg. 1995;109:877–84.
Kawachi Y, Tominaga R, Hisahara M, Nakashima A, Yasui H, Tokunaga K, et al. Excellent durability of the Hancock porcine bioprosthesis in the tricuspid position. A sixteen-year follow-up study. J Thoarc Cardiovasc Surg. 1992;104:1561–6.
Iscan ZH, Vural KM, Bahar I, et al. What to expect after tricuspid valve replacement? Long-term results. Eur J Cardiothorac Surg. 2007;32:296–300.
Spinale FG, Smith AC, Carabello BA, Crawford FA. Right ventricular function computed by thermodilution and ventriculography. J Thoarc Cardiovasc Surg. 1990;99:141–52.
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.
Kim SY, Kim KW, Lee SS, et al. Doppler sonography to diagnose venous congestion in a modified right lobe graft after living donor liver transplantation. Am J Reotenol. 2008;190:1010–7.
O’Grady JG, Alexander GJM, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439–45.
Edmunds LH Jr, Clark RE, Cohn LH, et al. Guidelines for reporting morbidity and mortality after cardiac valvular operations. J Thorac Cardiovasc Surg. 1996;112:708–11.
Chang BC, Lim SH, Yi G, et al. Long-term clinical results of tricuspid valve replacement. Ann Thorac Surg. 2006;81:1317–24.
Nooten GJY, Caes FL, Francois KJ, et al. The valve choice in tricuspid valve: 25 years of experience. Eur J Cardiothorac Surg. 1995;9:441–7.
Martin AP, Bartels M, Hauss J, Fangmann J. Iverview of the MELD score and the UNOS adult liver allocation system. Transplant Proc. 2007;39:3169–74.
Northup PG, Wanamaker RC, Lee VD, Adams RB, Berg CL. Model for end-stage liver disease (MELD) predicts non-transplant surgical mortality in patients with cirrhosis. Ann Surg. 2005;242:244–51.
Ailawadi G, Lapar DJ, Swenson BR, et al. Model for end-stage liver disease predicts mortality for tricuspid valve surgery. Ann Thorac Surg. 2009;87:1460–8.
McGrath LB, Chen C, Bailey BM, et al. Early and late phase events following bioprosthetic tricuspid valve replacement. J Card Surg. 1992;7:245–53.
Nakano K, Eishi K, Kosakai Y, Isobe F, Sasako Y, Nagata S, et al. Ten-year experience with the Carpentier-Edwards pericardial xenograft in the tricuspid position. J Thorac Cardiovasc Surg. 1996;111:605–12.
Chang BC, Lim SH, Kim DK, et al. Long-term results with St. Jude Medical and Carbomedics prosthetic heart valves. J Heart Valve Dis. 2001;10:185–95.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morimoto, N., Matsushima, S., Aoki, M. et al. Long-term results of bioprosthetic tricuspid valve replacement: an analysis of 25 years of experience. Gen Thorac Cardiovasc Surg 61, 133–138 (2013). https://doi.org/10.1007/s11748-012-0190-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11748-012-0190-4